<DOC>
	<DOCNO>NCT02445911</DOCNO>
	<brief_summary>This study consist multiple ascend oral dos 3 group , 29 day .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics Pharmacodynamics Multiple Ascending Doses KQ-791 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Have diagnosis Type 2 Diabetes Mellitus ( T2DM ) Be adult age 18 ( 19 Lincoln site ) 70 year Female participant must nonchildbearing potential , must either 1 ) postmenopausal amenorrhea least 1 year prior first dose Follicle Stimulating Hormone ( FSH ) serum level consistent postmenopausal status , 2 ) undergone one follow sterilization procedure least 6 month prior first dose : hysteroscopic sterilization bilateral tubal ligation bilateral salpingectomy hysterectomy bilateral oophorectomy Nonvasectomized male must agree use condom spermicide abstain sexual intercourse study 100 day beyond last dose study drug . ( No restriction require vasectomized male provide vasectomy perform 4 month prior first dose . A male vasectomized less 4 month prior first dose must follow restriction nonvasectomized male ) Males must agree donate sperm study 100 day follow last dose Have HbA1c value 7.010.0 % Be stable treatment regimen metformin , without diet/exercise , least 8 week Weigh 60 kilogram ( kg ) screen body mass index ( BMI ) great equal ( ≥ ) 25.0 less equal ( ≤ ) 40.0 kilograms/meters square ( kg/m2 ) Have laboratory test result within normal range T2DM population , abnormality deem clinically insignificant . Urine protein level must within normal limit Absence active diabetic retinopathy ( Stage 2 great International Clinical Disease Severity Scale Diabetic Retinopathy ) Are willing comply specific dietary restriction ( , [ ] able fast overnight least 812 hour several day [ ii ] able consume standard meal provide specified confinement day ) Have give write consent allow collection sample Peripheral Blood Mononuclear Cells ( PBMC ) analysis possible biomarkers/safety analysis Have give write informed consent approve institutional review board ( IRB ) govern site Are currently enrol clinical trial involve investigational product offlabel use drug device , concurrently enrol type medical research judge scientifically medically compatible study Participated ( define last dose study drug ) within 30 day prior dose clinical trial involve investigational product nonapproved use drug short halflife within 5 halflives investigational product halflife longer 6 day Have ( QTcF ) great ( &gt; ) 450 millisecond ( msec ) , clinical significant hypokalemia , family history long QT syndrome abnormality 12lead Electrocardiogram ( ECG ) Abnormal blood pressure ( sit ) define diastolic blood pressure &gt; 95 less ( &lt; ) 50 millimeter mercury ( mmHg ) and/or systolic blood pressure &gt; 160 &lt; 90 mmHg Have history presence cardiovascular , respiratory , hepatic , renal , gastrointestinal , endocrine , hematological , neurological disorder capable significantly alter absorption , metabolism , elimination drug Show evidence regular use know drug abuse and/or positive finding urinary drug screen Evidence human immunodeficiency virus ( HIV ) infection , hepatitis B , hepatitis C and/or positive result screen respective antibody HIV , hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody ( HCV ) Have anemia would interfere trial donate ≥500 mL blood within 56 day first dose donate plasma within 7 day first dose provide blood donation within last 30 day Have average weekly alcohol intake exceed 14 unit per week ( male ) 7 unit per week ( female ) [ 1 unit = 12 ounce ( oz ) 360 mL beer , 5 oz 150 mL wine , 1.5 oz 45 mL distil spirit ] unwilling stop alcohol consumption 48 hour prior first dose throughout study Consume 10 cigarette per day equivalent unable unwilling adhere restrict smoking policy Have &gt; 1 episode document severe hypoglycemia within last 6 month currently diagnose hypoglycemia unawareness Have follow clinical laboratory test result : estimate glomerular filtration rate ( eGFR ) &lt; 60 mL/min/1.73 m2 ( impaired renal function ) alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) level &gt; 1.5 time ( x ) upper limit normal ( ULN ) triglyceride ( TG ) &gt; 500 milligrams/deciliter ( mg/dL ) Have use insulin glycemic control medication , except metformin , diabetic control within 3 month Intend use nonsteroidal antiinflammatory drug ( except aspirin ) drug know prolong QT interval , herbal product , vitamin supplement change glucose level . The following medication allow participant : drug treatment hypertension lipid disorder ( except bile acid resin , niacin fish oil ) , platelet inhibitor , stable dose 12 week prior first dose thyroid replacement therapy , proton pump inhibitor , antidepressant , antihistamine , regularly take overthecounter ( OTC ) antiemetic cause correct QT interval ( QTc ) prolongation , provide drug specifically exclude hormonal replacement therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>